Form 8-K
8-K — RAPID MICRO BIOSYSTEMS, INC.
Accession: 0001380106-26-000067
Filed: 2026-05-13
Period: 2026-05-13
CIK: 0001380106
SIC: 3826 (LABORATORY ANALYTICAL INSTRUMENTS)
Item: Results of Operations and Financial Condition
Item: Financial Statements and Exhibits
Documents
8-K — rpid-20260513.htm (Primary)
EX-99.1 (rpid-20260331xexx991.htm)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K
8-K (Primary)
Filename: rpid-20260513.htm · Sequence: 1
rpid-20260513
0001380106false00013801062026-05-132026-05-13
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 13, 2026
RAPID MICRO BIOSYSTEMS, INC.
(Exact name of registrant as specified in its charter)
Delaware 001-40592 20-8121647
(State or other jurisdiction
of incorporation or organization) (Commission
File Number) (I.R.S. Employer
Identification No.)
25 Hartwell Avenue, Lexington, MA
02421
(Address of principal executive offices)
(Zip Code)
978-349-3200
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading
Symbols Name of each exchange on which
registered
Class A Common Stock, $0.01 par value per share RPID
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company þ
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02
Results of Operations and Financial Condition.
On May 13, 2026, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its its first quarter ended March 31, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety.
The information furnished under Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as otherwise expressly stated in such filing.
Item 9.01
Financial Statements and Exhibits.
(d)Exhibits.
Exhibit No. Description
99.1
Press Release of Rapid Micro Biosystems, Inc., dated May 13, 2026, related to its financial results for its first quarter ended March 31, 2026.
104
Cover Page Interactive Data File (formatted as inline XBRL)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
RAPID MICRO BIOSYSTEMS, INC.
Date: May 13, 2026 By: /s/ Sean Wirtjes
Sean Wirtjes
Chief Financial Officer
EX-99.1
EX-99.1
Filename: rpid-20260331xexx991.htm · Sequence: 2
Document
Exhibit 99.1
Rapid Micro Biosystems Reports First Quarter 2026 Financial Results
•Reports first quarter 2026 total revenue of $8.0 million, representing 11% growth compared to the first quarter of 2025
◦Placed 6 Growth Direct systems in the first quarter 2026 compared to 3 systems in the first quarter of 2025
•First quarter 2026 product revenue increased 36% year-over-year; consumable revenue increased over 30%
•First quarter 2026 recurring revenue increased 28% year-over-year; comprised 63% of total revenue
•First quarter 2026 product gross margin percentage increased 15-percentage points; consumable gross margin increased 33-percentage points
•Advanced strategic collaboration with MilliporeSigma with execution of Services Agreement
•Reaffirms full year 2026 total revenue guidance range of $37.0 million to $41.0 million including a range of 30 to 38 Growth Direct system placements
•Reaffirms full year 2026 gross margin percentage guidance of approximately 20%, with Q4 2026 exit rate in mid-20% range
Lexington, MA, May 13, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the first quarter ended March 31, 2026.
"Our first quarter results reflect strong and consistent execution across the business," said Robert Spignesi, President and CEO. "Strong consumable revenue drove nearly 30% growth in recurring revenue, underscoring the strength of our installed base and utilization trends. We continue to see robust customer interest in QC automation and are increasingly engaged in strategic discussions with customers on enterprise-level deployments of the Growth Direct platform and broader integration into company-wide automation strategies."
First Quarter Financial Results
Total revenue for the first quarter of 2026 increased 11.1% to $8.0 million compared to $7.2 million in the first quarter of 2025. The Company placed six new Growth Direct® systems and completed the validation of five customer systems compared to three placements and nine validations in the first quarter of 2025. Product revenue increased 36.0% to $5.6 million, compared to $4.1 million in the first quarter of 2025. Service revenue declined 21.9% to $2.4 million, compared to $3.1 million in the first quarter of 2025. The decline was primarily due to lower validation activity in the quarter, compared to the prior year. Recurring revenue increased 27.7% to $5.1 million, compared to $4.0 million in the first quarter of 2025.
Total cost of revenue was $7.6 million in the first quarter of 2026, an increase of 12.2% compared to $6.8 million in the first quarter of 2025. Gross margin was 4.6%, or $0.4 million, compared to 5.6%, or $0.4 million in the first quarter of 2025.
Total operating expenses increased by 17.9% to $14.2 million in the first quarter of 2026, compared to $12.1 million in the first quarter of 2025. General and administrative expenses increased by 30.8%, research and development expenses decreased by 7.3%, and sales and marketing expenses increased by 24.4%, in each case compared to the first quarter of 2025.
Net loss for the first quarter of 2026 was $14.3 million and net loss per share was $0.31, compared to a net loss of $11.3 million and net loss per share of $0.26 in the first quarter of 2025.
Cash, cash equivalents, short-term investments, and restricted cash were approximately $23 million as of March 31, 2026.
Full Year 2026 Outlook
The Company is reaffirming its full year 2026 total revenue guidance range of $37.0 million to $41.0 million including a range of 30 to 38 Growth Direct system placements, at least 25 system validations and gross margin percentage of approximately 20%.
Company Presentation Available
The Company has posted an updated presentation, titled Rapid Micro Biosystems Corporate Presentation - May 2026, to its Investor Relations website. The presentation includes a highlights of first quarter 2026 results and the Company's outlook for the second quarter and full year 2026.
This presentation is available at https://investors.rapidmicrobio.com/news-and-events/presentations
Webcast Details
The Company will host a conference call before the market opens today, May 13, 2026, at 4:30 p.m. ET to discuss its first quarter 2026 financial results. The live call is accessible on the Company’s website at investors.rapidmicrobio.com and will be archived and available for replay for one year.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered in Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.
Rapid Micro Biosystems intends to use the Investor Relations page of its website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor its website in addition to following press releases, filings with the Securities and Exchange Commission (“SEC”), public conference calls, presentations and webcasts.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the Company’s guidance, including with respect to full year 2026 total revenue, gross margin, number of Growth Direct placements and system validations; and the Company's growth outlook in future periods.
In some cases, you can identify forward-looking statements by terminology such as “outlook,” “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including, but not limited to risks related to, the Company's ability to achieve positive cash flow; the Company's ability to achieve its business objectives; the Company's significant losses since inception; the Company’s ability to meet its publicly announced guidance and other expectations about its business and operations; the Company's ability to fulfill customer orders on its anticipated timelines or at all; the impact of the Company's existing and any future indebtedness on its ability to operate its business; the Company’s ability to access any future tranches under its debt facility and to comply with all of its obligations thereunder; the Company’s limited experience in marketing and sales and the effectiveness of its sales processes; the Company’s need to develop new products and adapt to technological changes; the Company’s ability to establish and maintain its position as a leading provider of automated microbial quality control testing; the Company’s ability to maintain its manufacturing
facility; the Company's ability to improve the gross margins of its products and services; risks related to third-parties; the Company’s ability to retain key management and other employees; risks related to regulatory and intellectual property matters; risks related to supply chain disruptions and the impact of inflation; risks associated with macroeconomic events and uncertainty, including with respect to tariff and trade policy in the U.S. and abroad, as well as activity in the Company's industry and in the general economy; and the other important factors outlined under the caption “Risk Factors” in the Company’s Quarterly Report on Form 10-Q filed with the SEC, as such factors may be updated from time to time in its other filings with the SEC, which are available on the SEC's website at www.sec.gov and the Investor Relations page of its website at investors.rapidmicrobio.com. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.
Investor Contact
Michael Beaulieu, CFA
Vice President, Investor Relations and Corporate Communications
investors@rapidmicrobio.com
Media Contact
media@rapidmicrobio.com
RAPID MICRO BIOSYSTEMS, INC.
Unaudited Condensed Consolidated Statements of Operations
(in thousands, except share and per share amounts)
Three Months Ended March 31,
2026 2025
Revenue:
Product revenue $ 5,578 $ 4,101
Service revenue 2,424 3,104
Total revenue 8,002 7,205
Cost of revenue:
Cost of product revenue 6,025 5,029
Cost of service revenue 1,606 1,772
Total cost of revenue 7,631 6,801
Gross margin 371 404
Operating expenses:
Research and development 3,359 3,624
Sales and marketing 3,422 2,751
General and administrative 7,442 5,690
Total operating expenses 14,223 12,065
Loss from operations (13,852) (11,661)
Other income (expense):
Interest income 256 466
Interest expense (639) (12)
Other expense, net (32) (49)
Total other income (expense), net (415) 405
Loss before income taxes (14,267) (11,256)
Income tax expense 8 7
Net loss $ (14,275) $ (11,263)
Net loss per share — basic and diluted $ (0.31) $ (0.26)
Weighted average common shares outstanding — basic and diluted 45,433,800 43,993,359
RAPID MICRO BIOSYSTEMS, INC.
Unaudited Condensed Consolidated Balance Sheets
(in thousands)
March 31,
2026 December 31,
2025
Assets
Current assets:
Cash and cash equivalents $ 13,815 $ 20,030
Short-term investments 9,134 18,266
Accounts receivable 6,367 3,134
Inventory, net 17,447 17,593
Prepaid expenses and other current assets 2,463 2,145
Total current assets 49,226 61,168
Property and equipment, net 8,770 8,972
Right-of-use assets 3,838 4,109
Other long-term assets 245 319
Restricted cash 284 284
Total assets 62,363 74,852
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable $ 4,670 $ 4,139
Accrued expenses and other current liabilities 6,495 8,316
Deferred revenue 6,634 4,734
Lease liabilities, short-term 1,320 1,298
Total current liabilities 19,119 18,487
Lease liabilities, long-term 3,337 3,674
Notes payable, net 19,053 18,902
Warrant liability 116 186
Other long-term liabilities 340 397
Total liabilities 41,965 41,646
Total stockholders’ equity 20,398 33,206
Total liabilities and stockholders’ equity $ 62,363 $ 74,852
RAPID MICRO BIOSYSTEMS, INC.
Unaudited Cash, Cash Equivalents and Investments
(in thousands)
March 31,
2026 December 31,
2025
Cash and cash equivalents $ 13,815 $ 20,030
Short-term investments 9,134 18,266
Restricted cash
284 284
Cash, cash equivalents, investments and restricted cash $ 23,233 $ 38,580
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 7
v3.26.1
Cover Page
May 13, 2026
Cover [Abstract]
Document Type
8-K
Document Period End Date
May 13, 2026
Entity Registrant Name
RAPID MICRO BIOSYSTEMS, INC.
Entity Incorporation, State or Country Code
DE
Entity File Number
001-40592
Entity Tax Identification Number
20-8121647
Entity Address, Address Line One
25 Hartwell Avenue,
Entity Address, City or Town
Lexington,
Entity Address, State or Province
MA
Entity Address, Postal Zip Code
02421
City Area Code
978
Local Phone Number
349-3200
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Class A Common Stock, $0.01 par value per share
Trading Symbol
RPID
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
true
Entity Ex Transition Period
false
Entity Central Index Key
0001380106
Amendment Flag
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details
Name:
dei_EntityExTransitionPeriod
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration